MHRA guidance on coronavirus (COVID | 合法藥品大搜索
2020年3月19日—TheNationalInstituteforBiologicalStandardsandControl(NIBSC),acentreoftheMedicinesandHealthcareproductsRegulatoryAgency,also ...
24 June 2022ADR report updated to include data up to and including 15 June 2022.
16 September 2021Added new page - Access Consortium: Alignment with ICMRA consensus on immunobridging for authorising new COVID-19 vaccines under Vaccines and vaccines safety.
22 June 2021Linked to the new Temporary advice for management of oral retinoid medicines during the COVID-19 pandemic guidance, in the Medicines and COVID-19 section
4 June 2021Added "The MHRA concludes positive safety profile for Pfizer/BioNTech vaccine in 12- to 15-year-olds" to the vaccines and vaccine safety collection
28 May 2021Medicines and Healthcare products Regulatory Agency | 合法藥品大搜索
Welcome to our new MHRA website | 合法藥品大搜索
Services and information | 合法藥品大搜索
About us | 合法藥品大搜索
MHRA guidance on coronavirus (COVID | 合法藥品大搜索
New guidance and information for industry from the MHRA ... | 合法藥品大搜索
Latest from Medicines and Healthcare products Regulatory ... | 合法藥品大搜索
Medicines and Healthcare products Regulatory Agency ... | 合法藥品大搜索
MHRA Products | 合法藥品大搜索
MHRA:MHRA是英國葯監機構的簡稱,全稱為Medicines and ... | 合法藥品大搜索
【樂拿舒注射劑 10,000 K.U.】急性白血病(包括由慢性白血病轉變成急性者)惡性淋巴腫。
藥品名稱:樂拿舒注射劑10,000K.U.許可證字號:衛署藥輸字第021032號許可證種類:製 劑適應症:急性白血病(包括由慢性白血病轉...
【樂拿舒注射劑】急性白血病(包括由慢性白血病轉變成急性者)惡性淋巴腫
藥品名稱:樂拿舒注射劑許可證字號:衛署藥輸字第018780號許可證種類:製 劑適應症:急性白血病(包括由慢性白血病轉變成急性者...